Adenosine receptor agonists

Bibliography

• UZERMAN AP VAN DER WENDEN NM: Modulators of adenosine uptake, release and inactivation. In: Purinergic Approaches in Experimental Therapeutics. Jacobson KA, Jarvis MF (Eds), Wiley-Liss, Inc., (1997):129–148.
   Google Scholar
• FREDHOLM BB, ARSLAN G, HALLDNER L, KULL B, SCHULTE G, WASSERMAN W: Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg Arch Pharmacol (2000) 362:364–374.
   PubMed Web of Science ®Google Scholar
• POULSEN S, QUINN RI: Adenosine receptors: new opportunities for future drugs. Biorg. Med. Chem. (1998) 6:619–641.
   PubMed Web of Science ®Google Scholar
• •Therapeutic potential of adenosine receptor agonists and antagonists.
   Google Scholar
• KLOTZ KN: Adenosine receptors and their ligands. Naurlyn-Schmiedeberg Arch Pharmacol. (2000) 362:382–391.
   PubMed Web of Science ®Google Scholar
• FREDHOLM BB, ARSLAN G, KULL B, SVENNINGSON P: Locating the neuronal targets for caffeine. Drug Dev. Res. (1998) 45:324–328.
   Web of Science ®Google Scholar
• MULLER CE: Adenosine receptor ligands-recent developments part I. agonists. Curr. Med. Chem. (2000) 7:1269–1288.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review with excellent summary table of adenosine receptor agonists affinities and selectivities.
   Google Scholar
• HESS S: Recent advances in adenosine receptor antagonist research. Expert Opin. Ther Patents (2000) 11(10):1533–1561.
   Web of Science ®Google Scholar
• ••Comprehensive review on adenosine receptor antagonists and therapeutic applications.
   Google Scholar
• LINDEN J: Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trendy Pharmacol Li. (1994) 15:298–306.
   PubMed Web of Science ®Google Scholar
• OLAH ME, STILES GL: The role of receptor structure in determining adenosine receptor activity. Pharmacol Therapeutics (2000) 85:55–75.
   PubMed Web of Science ®Google Scholar
• •Review with summary of site-directed mutagenesis studies of adenosine receptors.
   Google Scholar
• PALMER TM, STILES GL: Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A(3) adenosine receptor. Mal Pharmacol (2000) 57:539–545.
   PubMed Web of Science ®Google Scholar
• RAMKUMAR V, OLAH ME, JACOBSON KA, STILES GL: Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Md. Pharmacol. (1991) 40:639–647.
   Google Scholar
• BARALDI PG, CACCIARAB, ROMAGNOLI R, SPALLUTO G: Aland A3 receptor agonists: an overview. Expert Opiri. Ther. Patents (1999) 9(5):515–527.
   Web of Science ®Google Scholar
• •SAR of A1 and A3 adenosine receptor agonists and therapeutic applications.
   Google Scholar
• SNOWDY S, LIANG HX, BLACKBURN B et al.: A comparison of an A1 adenosine receptor agonist (CVT-501) with diltiazem for slowing AV nodal conduction in guinea-pig. Br. J. Pharmacol. (1999) 126:137–146.
   PubMed Web of Science ®Google Scholar
• KNUTSEN US, LAU J, PETERSON H et al.: N-Substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects. (1998)1 Med. Chem. 42: 3463–3477.
   Google Scholar
• VAN DER WENDEN EM, CARNIELLI M, ROELEN HCPF et al.: 5'-substituted adenosine analogs as new high affinity partial agonists for the adenosine A1 receptor 1. Med. Chem. (1998) 41:102–108.
   Google Scholar
• VITTORI S, LORENZEN A, STANNEK C et al.: N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A1 adenosine receptor 1. Med. Chem. (2000) 43:250–260.
   Web of Science ®Google Scholar
• GAO Z, LIZ, BAKER SP etal.: Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. j Pharmacol. Esp. Ther. (2001) 298:209–218.
   Google Scholar
• •Discussion of rationale for using lower affinity A2A agonists as myocardial imaging agents.
   Google Scholar
• CRISTALLI G, ELEUTERI A, VITTORI S, VOLPINI R, LOHSE MJ, KLOTZ K-N: 2-Alkynyl derivatives of adenosine and adenosine-5'-N-eethyluronamides as selective agonists at A2 adenosine receptors. 1. Med. Chem. (1992) 35:2363–2368.
   Google Scholar
• RIEGER JM, BROWN ML, SULLIVAN GW, LINDEN J, MACDONALD TL: Design, synthesis and evaluation of novel A2A adenosine receptor agonists. 1. Med. Chem. (2001) 44:531–539.
   Google Scholar
• OKUSA MD, LINDEN J, MACDONALD T, HUANG L: Selective A2A adenosine receptor activation reduces ischaemia-reperfusion injury in rat kidney. Am. I Physiol (1999) 277:F404–F412.
   PubMedGoogle Scholar
• GLOVER DK, RUIZ M, TAKEHANA T et al.: Pharmacological stress myocardial perfusion imaging with the potent and selective A2A adenosine receptor agonists ATL193 and ATL146e administered by either iv. infusion or bolus injection. Circulation (2001) 104:1181–1187.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Selective A2A receptor agonists as inhibitors of cellular activation. Expert Opiri. Ther. Patents (2000) 10(5):723–728.
   Web of Science ®Google Scholar
• •Synthesis and SAR of An adenosine receptors agonists developed by Glaxo.
   Google Scholar
• KEELING SE, ALBINSON FD, AYRES BE etal.: The discovery and synthesis of highly potent A2A receptor agonists. Biorg. Med. Chem. Lett. (2000) 10:403–406.
   Google Scholar
• LINDEN J, THAI T, FIGLER H, JINX, ROBEVA AS: Characterization of human A(213) adenosine receptors: radioligand binding, western blotting and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Ma. Pharmacol. (1999) 56:705–713.
   PubMed Web of Science ®Google Scholar
• KIM Y-C, JI X-D, MELMAN N, LINDE J, JACOBSON KA: Anilide derivatives of 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B receptors. 1. Med. Chem. (2000) 43:1165–1172.
   Google Scholar
• GALLO-RODRIGUEZ C, JI X-D, MELMAN N et al.: Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. I Med. Chem. (1994) 37:636–646.
   PubMed Web of Science ®Google Scholar
• KLOTZ K-N, HESLING J, HEGLER J etal.: Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Nauriyri-Schmiedeberg Arch. Pharmacol. (1998) 357:1–9.
   Google Scholar
• KIM HO, JI X-D, SIDDIQI SM, OLAH ME, STILES GL, JACOBSON KA: 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. 1. Med. Chem. (1994) 37:3614–3621.
   Google Scholar
• BARALDI PG, CACCIARA B, PINEDA DE LAS INFANTAS MJ etal.: Synthesis and biological activity of a new series of N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists. 1. Med. Chem. (1998) 41:3174–3185.
   Google Scholar
• BARALDI PG, CACCIARA B, ROMAGNOLI R et al: A3 adenosine receptor ligands: history and perspectives. Med. Res. Rev (2000) 20(2):103–128.
   PubMed Web of Science ®Google Scholar
• •Synthesis and SAR of A3 adenosine receptor agonists and antagonists.
   Google Scholar
• FISHMAN P, BAR-YEHUDA S, BARER F, MADI L, MULTANI AS, PATHAK S: The A3 receptor as a new target for cancer therapy and chemoprotection. Esp. Cell Res. (2001) 269:230–236.
   PubMed Web of Science ®Google Scholar
• •Interesting biological activity and therapeutic indication for A3 agonists.
   Google Scholar
• DE ZWART M, KOUROUNAKIS A, KOOIJMAN H et al.: 5'-N-substituted carboxamidoadenosine as agonist for adenosine receptors. 1. Med. Chem. (1999) 42:1384–1392.
   Google Scholar
• VAN TILBURG EW, VON FRITAG DRABBE KUNZEL JK, DE GOOTE M, VOLLINGA RC, LORENZEN A, IJZERMAN AP: N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor. I Med. Chem. (1999) 42:1393–1400.
   PubMed Web of Science ®Google Scholar